US Patent Office grants Patent for GQ Bio’s Lead Product

The United States Patent and Trademark Office grants patent covering GQ Bio’s lead gene therapy candidate GQ-501 for treatment of osteoarthritis.

The patent protects GQ Bio’s lead product candidate GQ-501 for treatment of osteoarthritis and its veterinary analogs. GQ-501 is a high-capacity gene therapy vector expressing proteoglycan 4 and interleukin-1 receptor antagonist currently in development for treatment of osteoarthritis.

Securing intellectual protection in the US, which is the largest osteoarthritis market, represents a major milestone for GQ Bio. The patent for this technology was already granted in 2020 in Europe, which is the second largest market.